Merck ends development of cCAM compound

Merck & Co. Inc. (NYSE:MRK) terminated development of oncology candidate CM-24, spokesperson Pamela Eisele told BioCentury. Eisele said the mAb showed no signs of efficacy in a dose-ranging Phase I study in combination with Keytruda pembrolizumab to treat advanced or recurrent malignancies. She said the company's decision was not due to safety concerns...